2026-01-12 - Analysis Report
**Company Overview**
Johnson & Johnson is a multinational healthcare company.

**Return Rate Comparison**
* Ticker: JNJ
* Review Stock Return Rate: **50.20%**
* Comparison Stock (S&P 500, VOO) Return Rate: **94.03%**
* Divergence: **-44.83%** (difference in cumulative return)
* Relative Divergence: **24.60%** (24.6% of the maximum-minimum fluctuation range)

**Alpha, Beta Analysis**
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 6.0% | 16.8% | 3.0% | 0.7 | 310.9B |
| 2017-2019  | 18.0% | 16.8% | 1.0% | 0.7 | 351.4B |
| 2018-2020  | 19.0% | 16.8% | -2.0% | 0.7 | 379.2B |
| 2019-2021  | 32.0% | 10.7% | -12.0% | 0.6 | 412.2B |
| 2020-2022  | 8.0% | 13.8% | 10.0% | 0.5 | 425.6B |
| 2021-2023  | -18.0% | 13.8% | -19.0% | 0.3 | 377.6B |
| 2022-2024  | -30.0% | 13.8% | -50.0% | 0.2 | 348.4B |
| 2023-2025  | 30.0% | 13.8% | -32.0% | 0.1 | 498.6B |

**Recent Stock Price Fluctuations**
* Close: **$204.39**
* Last-market: {'price': 204.39, 'previousClose': 205.75, 'change': -0.66}
* 5-day SMA: **$205.35**
* 20-day SMA: **$207.70**
* 60-day SMA: **$199.99**

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence, Expected_Return**
* Market Risk Indicator (MRI): **0.70** (0.9~1.0: High Investment Recommended, 0.7~0.9: Medium Investment, 0.4~0.7: Low Investment, <0.4: Very Risky)
* RSI: **38.51**
* PPO: **-0.36**
* Hybrid Signal: Buy (Cash 0%)
Risk Level: Medium (MRI 0.70)
Recent (20 days) relative divergence change: **-6.80** (-): worsening
7-day Rank change: **-3** (-): rank down
7-day Dynamic Expected Return change: **-22.70** (-): worsening
Expected Return (%): **-74.90%**, Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.

**Recent News & Significant Events**
* [2026-01-05] Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note
* [2026-01-11] CX Institutional Purchases 5,165 Shares of Johnson & Johnson $JNJ
* [2025-12-30] More Upside For JNJ Stock In 2026?
* [2026-01-11] Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday
* [2026-01-07] Has Johnson & Johnson (JNJ) Run Too Far After Its 44.3% One-Year Surge?
* [2026-01-09] Millions to get cheaper medicines as J&J builds new drug plants in U.S.

**Analyst Opinions**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): **2.16** (~Buy)
- Opinions: **24**
- Target Price (avg/high/low): **212.00** / **240.00** / **155.00**

**Recent Earnings Analysis**
| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-22 | 2.14 | $23.99B |
| 2025-07-24 | 2.3 | $23.74B |
| 2025-04-23 | 4.57 | $21.89B |
| 2024-10-23 | 1.12 | $22.47B |
| 2025-10-22 | 1.12 | $22.47B |

The earnings per share (EPS) has been mostly increasing, with a peak of **4.57** in Q2 2025 and a dip to **1.12** in Q4 2024 and Q4 2025. Revenue has been stable at around **$22-23.99B**.

**Financial Information = 5**

**Revenue and Profitability**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |
| 2024-09-30 | $22.47B | 69.01% |

Profit margin has been stable at around **66-70%**, with a peak of **69.56%** in Q3 2025.

**Capital and Profitability**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $79.28B | 6.50% |
| 2025-06-30 | $78.47B | 7.06% |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80% |
| 2024-09-30 | $70.16B | 3.84% |

Return on Equity (ROE) has been volatile, with a peak of **14.08%** in Q3 2025 and a dip to **3.84%** in Q3 2024.

**Comprehensive Analysis (Summary of previous items)**
The stock has shown a cumulative return of **50.20%**, lower than the S&P 500's **94.03%**. The company's financials have been stable, with revenue and profit margin around **$22-23.99B** and **66-70%** respectively. However, the ROE has been volatile. The recent news and significant events have been mixed, with some positive and negative news. The analyst opinions are generally positive, with a consensus of **Buy** and a target price of **$212.00**. The hybrid signal is **Buy**, and the risk level is **Medium**. The expected return is **-74.90%**, suggesting that the stock may not perform well in the long term.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.